2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Barbara J. Gitlitz, MD, associate professor of Clinical Medicine, Keck Hospital of USC Norris Comprehensive Cancer Center, discusses treating patients with EGFR exon 20 insertion mutations in lung cancer.
Barbara J. Gitlitz, MD,
a
ssociate
p
rofessor of Clinical Medicine, Keck Hospital of USC Norris Comprehensive Cancer Center, discusses treating patients with
EGFR
exon 20 insertion mutations in lung cancer.
Exon 20 insertion mutations are the third most common type of
EGFR
mutation that
patients with
lung cancer present with, says Gitlitz. While this mutation will show up in a report as an
EGFR
mutation, it does not respond to any currently available EGFR inhibitors. It is important to be aware that a patient with an
EGFR
mutation has an
e
xon 20 insertion, explains Gitlitz.
Exon 20 insertion mutations are currently a target without a treatment, says Gitlitz. More clinical trials are needed.